Benefits and Risks of Aliskiren Treatment in Patients With Type 2 Diabetes: Analyses of the 3A Registry

  • Iris Kistner, Uwe Zeymer, Ralf Dechend, Ina Hagedorn, Thomas Riemer, Peter Bramlage, David Pittrow, Jochen Senges, Roland E. Schmieder
  • Journal of Clinical Hypertension, April 2016, Wiley
  • DOI: 10.1111/jch.12828

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

The following have contributed to this page: Peter Bramlage